TITLE

Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer

AUTHOR(S)
Haydon, A. M. M.; Maclnnis, R. J.; English, D. R.; Morris, H.; Giles, G. G.
PUB. DATE
May 2006
SOURCE
Gut;May2006, Vol. 55 Issue 5, p689
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Recent reports have shown that physical activity improves the outcome of patients with colorectal cancer as well as breast and prostate cancer. However, the mechanisms whereby physical activity reduces cancer mortality are not well established. Methods: Incident cases of colorectal cancer were identified among participants of the Melbourne Collaborative Cohort Study, a prospective cohort study of 41 528 Australians recruited from 1990 to 1994. Information on tumour site and stage, treatments given, recurrences, and deaths were obtained from systematic review of the medical records. Baseline assessments of physical activity and body size were made, and cases with available plasma had pre-diagnosis insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels measured. We assessed associations between these hormones and colorectal cancer specific deaths with respect to physical activity. Results: A total of 526 cases of colorectal cancer were identified, of which 443 had IGF-1/IGFBP-3 levels measured. Median fallow up among survivors was 5.6 years. For the physically active, increasing IGFBP-3 by 26.2 nmol/l was associated with a 48% reduction in colorectal cancer specific deaths (adjusted hazard ratio (HR) 0.52 (0.33–0.83); p = 0.006). No association was seen for IGF-1 (adjusted HR 0.90 (0.55–1.45); p = 0.65). For the physically inactive, neither IGF-1 nor IGFBP-3 was associated with disease specific survival. Conclusions: This study supports the hypothesis that the beneficial effects of physical activity in reducing colorectal cancer mortality may occur through interactions with the insulin-like growth factor axis and in particular IGFBP-3.
ACCESSION #
20739319

 

Related Articles

  • IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Suzuki, Hiromu; Igarashi, Shinichi; Nojima, Masanori; Maruyama, Reo; Yamamoto, Eiichiro; Kai, Masahiro; Akashi, Hirofumi; Watanabe, Yoshiyuki; Yamamoto, Hiroyuki; Sasaki, Yasushi; Itoh, Fumio; Imai, Kohzoh; Sugai, Tamotsu; Shen, Lanlan; Issa, Jean-Pierre J.; Shinomura, Yasuhisa; Tokino, Takashi; Toyota, Minoru // Carcinogenesis;Mar2010, Vol. 31 Issue 3, p342 

    A subset of colorectal cancers (CRCs) show simultaneous methylation of multiple genes; these tumors have the CpG island methylator phenotype (CIMP). CRCs with CIMP show a specific pattern of genetic alterations, including a high frequency of BRAF mutations and a low frequency of p53 mutations....

  • IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Probst-Hensch, N M; Yuan, J-M; Stanczyk, F Z; Gao, Y-T; Ross, R K; Yu, M C // British Journal of Cancer;12/1/2001, Vol. 85 Issue 11, p1695 

    This is the first study to investigate the associations of IGF-1, IGF-2 and IGFBP-3 concentrations with the risk of colorectal cancer in prospectively collected blood samples from an Oriental population. Between 1986 and 1989 serum samples were collected at baseline from 18 244 men, aged 45-65...

  • Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells. André, Frédéric; Janssens, Barbara; Bruyneel, Erik; Gespach, Christian; Mareel, Marc; Bracke, Marc; van Roy, Frans // Oncogene;2/12/2004, Vol. 23 Issue 6, p1177 

    The mechanisms by which growth factors cooperate with cell adhesion molecules to modulate epithelial cell motility remain poorly understood. Here, we investigated the role of the E-cadherin/catenin complex in insulin-like growth factor (IGF-I)-dependent cell migration and invasion. We used...

  • The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Davies, M.; Gupta, S.; Goldspink, G.; Winslet, M. // International Journal of Colorectal Disease;May2006, Vol. 21 Issue 3, p201 

    This article presents the results of a study which examined the correlation of the insulin-like growth factor (IGF) system with the development of colorectal cancer and its impact on the field of endocrinology. It discussed the epidemiological properties of insulin-like growth factor-binding...

  • IGFBP3 Promoter Methylation in Colorectal Cancer: Relationship with Microsatellite Instability, CpG Island Methylator Phenotype, and p53. Kawasaki, Takako; Nosho, Katsuhiko; Ohnishi, Mutsuko; Suemoto, Yuko; Kirkner, Gregory J.; Fuchs, Charles S.; Ogino, Shuji // Neoplasia;Dec2007, Vol. 9 Issue 12, p1091 

    Insulin-like growth factor binding protein 3 (IGFBP3), which is induced by wild-type p53, regulates IGF and interacts with the TGF-β pathway. IGFBP3 promoter methylation may occur in colorectal cancer with or without the CpG island methylator phenotype (CIMP), which is associated with...

  • Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomas. Keku, Temitope O.; Sandler, Robert S.; Simmons, James G.; Galanko, Joseph; Woosley, John T.; Proffitt, Michelle; Omofoye, Oluwaseun; McDoom, Maya; Lund, Pauline K. // BMC Cancer;2008, Vol. 8, Special section p1 

    Background: IGF binding protein-3 (IGFBP-3) regulates the bioavailability of insulin-like growth factors I and II, and has both anti-proliferative and pro-apoptotic properties. Elevated plasma IGFBP-3 has been associated with reduced risk of colorectal cancer (CRC), but the role of tissue...

  • Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Jones, H. E.; Gee, J. M. W.; Barrow, D.; Tonge, D.; Holloway, B.; Nicholson, R. I. // British Journal of Cancer;7/17/2006, Vol. 95 Issue 2, p172 

    Resistance to antiepidermal growth factor (EGFR) strategies is an emerging clinical problem. Using human colorectal cancer (CRC) cells, we evaluated the involvement of the insulin receptor isoform-A (InsR-A) in de novo resistance to gefitinib, an EGFR tyrosine kinase inhibitor. Challenging the...

  • Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Renehan, A G; Jones, J; Potten, C S; Shalet, S M; O'Dwyer, S T // British Journal of Cancer;11/15/2000, Vol. 83 Issue 10, p1344 

    This study explored the relationships of serum insulin-like growth factors, IGF-I and IGF-II, and their binding proteins (IGFBP)-2 and IGFBP-3, with key clinicopathological parameters in 92 patients with colorectal cancer (cases). Comparisons were made with 57 individuals who had a normal...

  • Insulin-Like Growth Factor-I: a Key Regulator of Human Cancer Risk? Burroughs, Kevin D.; Dunn, Sandra E.; Barrett, J. Carl; Taylor, Jack A. // JNCI: Journal of the National Cancer Institute;04/07/99, Vol. 91 Issue 7, p579 

    Focuses on the results of a study that show an association between colorectal cancer risk in men and elevated plasma levels of insulin-like growth factor-I (IGF-I) and decreased plasma levels of IGF-binding protein-3. Synthesis of IGF-I; Interpretation of the research findings; Role of IGF...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics